(lp0
S'Vivus Inc. stock rises 4.6% after regaining certain commercial rights for ... MarketWatch - Mar 27, 2017 Vivus Inc. VVUS, +0.97% shares rose 4.6% in premarket trade Monday after the company said it would regain the right to commercialize and promote erectile dysfunction drug Stendra in Africa, the Middle East, Turkey and Russia from Sanofi S.A.'
p1
aS"How VIVUS Inc  Delivered A Better ROE Than Its Industry? Simply Wall St - Mar 8, 2017 Over the past 12 months, VIVUS Inc  generated an ROE of 273.4%, implying the company created 273.4 cents on every dollar of shareholders' invested capital.VIVUS, Inc.  Posts Quarterly Earnings Results, Beats Estimates By $0.31 EPS - BNB Daily "
p2
aS'Market Spotlight: Focusing on Shares of VIVUS, Inc.  BVN - 17 hours ago Looking at shares of VIVUS, Inc. , the company presently has a Gross Margin  ratio of 0.371697. This number is calculated from the research by University of Rochester professor Robert Novy-Marx.'
p3
aS'Analyst Advice And Earnings Insight: VIVUS, Inc. , Hanmi Financial ... Post Analyst - 15 hours ago VIVUS, Inc. has a consensus outperform rating from 2 Wall Street analysts, and the number of shares currently sold short amount to at least 6.01% of shares outstanding.'
p4
aS'Growth Analysis of: VIVUS Inc.  StandardOracle - Apr 5, 2017 VIVUS Inc.  plummeted -1.85 percent and ended the day at $1.06. The Average Volume of the company is 544.73 Million and P/E  ratio is 5.1, while Forward P/E ratio is 0. WallachBeth Downgrade its coverage for VIVUS Inc. &nbsp;...'
p5
aS'Vivus Inks Deal For Stendra - Why Street Reaction Is Muted Seeking Alpha - Oct 4, 2016 Vivus  announced today that it has reached a deal withy Metuchen Pharmaceuticals for the rights to the erectile dysfunction drug Stendra in the United States, Canada, South America, and India.VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial ... - Marketwired VIVUS Licenses Stendra Rights to Metuchen Pharmaceuticals - Nasdaq'
p6
aS"Alimera Sciences, Inc. and VIVUS Inc. Head to Head Compare CML News - Apr 15, 2017 Alimera Sciences Inc has a higher fundamental rating than VIVUS Inc which has an impact on the head-to-head comparison. The CML Star Rating is an objective, quantifiable measure of a company's operating and financial condition."
p7
aS'VIVUS, Inc. Reacquires STENDRA  Commercial Rights from Sanofi Marketwired  - Mar 27, 2017 CAMPBELL, CA-- - VIVUS, Inc.  , announced today that it reached an agreement with Sanofi to return the commercial rights for STENDRA in Africa, the Middle East, Turkey and the&nbsp;...'
p8
aS"Thursday's Market Insights: Apricus Biosciences Inc , VIVUS, Inc. (VVUS ... Smarter Analyst - Mar 9, 2017 Apricus Biosciences Inc  shares are rising by 3% in Thursday's trading on the news that Apricus has completed the sale to Ferring International of its topical cream Vitaros.VIVUS  Posts Strong Profit Growth; Apricus Biosciences  Soars on ... - Galaxy Stocks  "
p9
aS'Investors Must See: VIVUS Inc.  StandardOracle - Apr 3, 2017 VIVUS Inc.  jumped 2.75 percent and ended the day at $1.12. The Average Volume of the company is 543.75 Million and P/E  ratio is 5.38, while Forward P/E ratio is 0. WallachBeth Downgrade its coverage for VIVUS Inc.  in a&nbsp;...VIVUS, Inc.  Trading Down 0% on Insider Selling - Sports PerspectivesShort Term Technical Outlook: ChemoCentryx, Inc. , VIVUS, Inc.  - Post Analyst'
p10
a.